Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Post-Operative Pain Overview | 12 | 1 |
| Therapeutics Development | 13 | 1 |
| Pipeline Products for Post-Operative Pain Overview | 13 | 1 |
| Post-Operative Pain Therapeutics under Development by Companies | 14 | 3 |
| Post-Operative Pain Pipeline Products Glance | 17 | 4 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Unknown Stage Products | 20 | 1 |
| Post-Operative Pain Products under Development by Companies | 21 | 3 |
| Post-Operative Pain Companies Involved in Therapeutics Development | 24 | 37 |
| AcelRx Pharmaceuticals, Inc. | 24 | 1 |
| Adynxx, Inc. | 25 | 1 |
| AngioChem Inc. | 26 | 1 |
| AskAt Inc. | 27 | 1 |
| Boehringer Ingelheim GmbH | 28 | 1 |
| Cara Therapeutics, Inc. | 29 | 1 |
| Colby Pharmaceutical Company | 30 | 1 |
| Cytogel Pharma, LLC | 31 | 1 |
| Dompe Farmaceutici S.p.A. | 32 | 1 |
| DURECT Corporation | 33 | 1 |
| Echo Pharmaceuticals B.V. | 34 | 1 |
| Fujimoto Pharmaceutical Corporation | 35 | 1 |
| Galleon Pharmaceuticals | 36 | 1 |
| Grunenthal GmbH | 37 | 1 |
| GW Pharmaceuticals Plc | 38 | 1 |
| Heron Therapeutics, Inc. | 39 | 1 |
| Immupharma Plc | 40 | 1 |
| Innocoll AG | 41 | 1 |
| INSYS Therapeutics, Inc. | 42 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 43 | 1 |
| Lipocure Ltd. | 44 | 1 |
| Liquidia Technologies, Inc. | 45 | 1 |
| Medtronic plc | 46 | 1 |
| Orbis Biosciences, Inc. | 47 | 1 |
| Orion Oyj | 48 | 1 |
| Pacira Pharmaceuticals, Inc. | 49 | 1 |
| PainReform Ltd. | 50 | 1 |
| Pharmazz, Inc. | 51 | 1 |
| PhytoHealth Corporation | 52 | 1 |
| Proteus SA | 53 | 1 |
| Recro Pharma, Inc. | 54 | 1 |
| Relmada Therapeutics, Inc. | 55 | 1 |
| Serina Therapeutics, Inc. | 56 | 1 |
| SteadyMed Therapeutics, Inc. | 57 | 1 |
| Takeda Pharmaceutical Company Limited | 58 | 1 |
| The Medicines Company | 59 | 1 |
| Trevena, Inc. | 60 | 1 |
| Post-Operative Pain Therapeutics Assessment | 61 | 12 |
| Assessment by Monotherapy Products | 61 | 1 |
| Assessment by Combination Products | 62 | 1 |
| Assessment by Target | 63 | 3 |
| Assessment by Mechanism of Action | 66 | 3 |
| Assessment by Route of Administration | 69 | 2 |
| Assessment by Molecule Type | 71 | 2 |
| Drug Profiles | 73 | 97 |
| (bupivacaine hydrochloride + meloxicam) Drug Profile | 73 | 2 |
| AM-4 Drug Profile | 75 | 1 |
| ANG-2002 Drug Profile | 76 | 1 |
| ARX-04 Drug Profile | 77 | 5 |
| AYX-1 Drug Profile | 82 | 2 |
| BI-1026706 Drug Profile | 84 | 1 |
| bupivacaine hydrochloride Drug Profile | 85 | 1 |
| bupivacaine hydrochloride Drug Profile | 86 | 1 |
| bupivacaine hydrochloride Drug Profile | 87 | 1 |
| bupivacaine hydrochloride Drug Profile | 88 | 1 |
| bupivacaine hydrochloride ER Drug Profile | 89 | 1 |
| bupivacaine hydrochloride SR Drug Profile | 90 | 5 |
| buprenorphine hydrochloride Drug Profile | 95 | 1 |
| CPC-123 Drug Profile | 96 | 1 |
| CR-4056 Drug Profile | 97 | 1 |
| Cyt-1010 Drug Profile | 98 | 2 |
| dexmedetomidine hydrochloride Drug Profile | 100 | 3 |
| DF-2755A Drug Profile | 103 | 1 |
| difelikefalin Drug Profile | 104 | 7 |
| difluprednate XR Drug Profile | 111 | 1 |
| dronabinol Drug Profile | 112 | 2 |
| Drug for Post Operative Pain Drug Profile | 114 | 1 |
| ECP-1014 Drug Profile | 115 | 1 |
| fadolmidine hydrochloride Drug Profile | 116 | 1 |
| fentanyl Drug Profile | 117 | 1 |
| GAL-044 Drug Profile | 118 | 1 |
| grapiprant Drug Profile | 119 | 2 |
| IPP-102199 Drug Profile | 121 | 1 |
| ketamine hydrochloride Drug Profile | 122 | 2 |
| ketorolac tromethamine Drug Profile | 124 | 1 |
| levorphanol tartrate ER Drug Profile | 125 | 2 |
| MDT-10013 Drug Profile | 127 | 1 |
| meloxicam Drug Profile | 128 | 3 |
| meloxicam ER Drug Profile | 131 | 1 |
| meloxicam ER Drug Profile | 132 | 1 |
| MR-309 Drug Profile | 133 | 2 |
| nabiximols Drug Profile | 135 | 7 |
| nalbuphine hydrochloride Drug Profile | 142 | 1 |
| neosaxitoxin Drug Profile | 143 | 2 |
| oliceridine Drug Profile | 145 | 5 |
| PMZ-2010 Drug Profile | 150 | 1 |
| RBM-004 Drug Profile | 151 | 1 |
| ropivacaine Drug Profile | 152 | 1 |
| ropivacaine ER Drug Profile | 153 | 1 |
| SER-226 Drug Profile | 154 | 1 |
| Small Molecule for Post-Operative Pain Drug Profile | 155 | 1 |
| sufentanil citrate Drug Profile | 156 | 8 |
| tapentadol hydrochloride Drug Profile | 164 | 2 |
| tramadol hydrochloride Drug Profile | 166 | 1 |
| tramadol hydrochloride ER Drug Profile | 167 | 1 |
| URB-937 Drug Profile | 168 | 1 |
| VVZ-149 Drug Profile | 169 | 1 |
| Post-Operative Pain Dormant Projects | 170 | 5 |
| Post-Operative Pain Discontinued Products | 175 | 1 |
| Post-Operative Pain Product Development Milestones | 176 | 10 |
| Featured News &Press Releases | 176 | 1 |
| Jun 13, 2016: Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug SyB P-1501 | 176 | 1 |
| Jun 08, 2016: Trevena Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain | 176 | 1 |
| Jun 06, 2016: Cara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain | 177 | 1 |
| Apr 20, 2016: Cara Therapeutics Announces Removal of FDA Clinical Hold on CLIN3001 Postoperative Pain Trial for I.V. CR845 | 177 | 1 |
| Apr 07, 2016: DURECT Announces POSIMIR Program Update | 178 | 1 |
| Mar 07, 2016: AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain | 179 | 1 |
| Mar 07, 2016: iX Biopharma Reports Positive Results From Multi-Dose Waferminetm Clinical Trial | 179 | 1 |
| Feb 25, 2016: AcelRx Pharmaceuticals Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis | 180 | 1 |
| Feb 25, 2016: Cara Therapeutics Provides Update on CLIN3001 Postoperative Pain Trial for I.V. CR845 | 180 | 1 |
| Feb 01, 2016: Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain | 181 | 1 |
| Jan 27, 2016: Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain | 182 | 1 |
| Jan 21, 2016: AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery | 182 | 1 |
| Dec 23, 2015: AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency | 183 | 1 |
| Dec 14, 2015: AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 | 183 | 1 |
| Nov 20, 2015: The Medicines Company Receives European Commission Approval for IONSYS 40 micrograms per dose transdermal system (fentanyl) to Treat Post-Operative Pain in Adult Hospitalized Patients | 184 | 2 |
| Appendix | 186 | 2 |
| Methodology | 186 | 1 |
| Coverage | 186 | 1 |
| Secondary Research | 186 | 1 |
| Primary Research | 186 | 1 |
| Expert Panel Validation | 186 | 1 |
| Contact Us | 186 | 1 |
| Disclaimer | 187 | 1 |